Drugs / Nelotanserin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02871427 | Oct 2016 → Jan 2019 | Lewy body dementia, Parkinson disease, REM sleep behavior disorder | Axovant Sciences Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02708186 | Mar 2016 → May 2018 | Lewy body dementia, Parkinson disease, REM sleep behavior disorder | Axovant Sciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02640729 | Dec 2015 → Nov 2017 | Charles bonnet syndrome, Lewy body dementia | Axovant Sciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00664664 | Apr → Oct 2008 | insomnia | Arena Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00452179 | Feb → Jun 2007 | insomnia | Arena Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nelotanserin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02640729 ↗ |
| Known as | APD125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452179 ↗ |
| Known as | Nelotanserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL598172 ↗ |
| Known as | Nelotanserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL598172 ↗ |
| Action | Inhibit | “a selective 5-HT (2A) inverse agonist” PMID 33714847 ↗ Feb 2021 |
| Modality | Small molecule | — CHEMBL598172 ↗ |
| Route | Oral | “once daily, oral, 20-mg tablets” NCT02640729 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor inverse agonist” CHEMBL598172 ↗ |